BJH / JLB | Team of Professors Jianxiang Wang and Shaowei Qiu at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Uncover Novel Mechanisms in t(8;21) AML and Identify Potential Therapeutic Targets

BJH / JLB | Team of Professors Jianxiang Wang and Shaowei Qiu at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Uncover Novel Mechanisms in t(8;21) AML and Identify Potential Therapeutic Targets

Acute myeloid leukemia, subtype M2b (AML-M2b), was first identified in 1959 by Professor Chongli Yang at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), based on clinical features, bone marrow morphology, and cytology. He termed it “subacute granulocytic leukemia.” In 1973, Rowley and colleagues abroad reported the same leukemia subtype through cytogenetic methods. By the late 1990s, the team led by Professor Jianxiang Wang demonstrated that the chromosomal translocation t(8;21) leads to rearrangement of the AML1 and ETO genes, producing the AML1-ETO (RUNX1::RUNX1T1) fusion gene—the molecular hallmark of AML-M2b. This marker has since been widely applied in differential diagnosis and minimal residual disease (MRD) monitoring.
Blood Science Update | Unexpected Poor Prognosis in ZNF618::NUTM1-Positive B-ALL: A Rare Case Defies Clinical Assumptions

Blood Science Update | Unexpected Poor Prognosis in ZNF618::NUTM1-Positive B-ALL: A Rare Case Defies Clinical Assumptions

ZNF618::NUTM1-rearranged B-cell lymphoblastic leukemia (B-ALL) is recognized as a rare but favorable subtype of pediatric leukemia. However, this new case report published in Blood Science challenges that prognostic certainty, documenting a 3-year-old patient whose disease proved resistant to conventional chemotherapy, multiple CAR-T therapies, and hematopoietic stem cell transplantation. The findings underscore the need to reassess expectations surrounding NUTM1 fusion-positive leukemias and investigate the biological complexity behind treatment failure.
Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress

Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress

From July 15 to 18, 2025, the annual global summit in the field of robotic surgery—the World Congress of the Society of Robotic Surgery (SRS)—was held in France, drawing together leading surgeons and pioneers in robotic technology from around the world. The event featured discussions on cutting-edge innovations and future trends, along with the presentation of dozens of state-of-the-art surgical robot platforms and their development teams. Representing one of China’s foremost urologic oncology institutions, the Department of Urology at Fudan University Shanghai Cancer Center, led by Professor Dingwei Ye, actively participated in this global exchange, showcasing China’s expertise and innovation on the international stage.